Founded in 2001, Zein is a National high-tech enterprise in Chongqing, which focused on research, production, sales and market.
Zein attaches great importance to new products R&D, owns all kinds of high-level professional and technical personnel, introduces national "Thousand people Program" experts and doctors, masters, returnees. Zein’s understudied projects involve chemical drugs of neural system, metabolic system and digestive system etc. The company establishes the traditional Chinese medicine famous prescription transformation center, mainly carries on research and development of the hospital traditional Chinese medicine preparation, the classical famous prescription, the traditional Chinese medicine new medicine and so on, has accumulated experience on the effective material separation purification, the formulation production process and specification study. It has obtained 33 new drug certificates, 32 clinical approvals and 51 production licenses and has already applied 57 Patents, in which 8 foreign patents and 19 domestic patents have been authorized, obtained 243 trademark authorizations.
The production capability of the API manufacturing base is more than 40 tons, and the new 82,000 m2 API manufacturing base that is under construction will increase the capability to 60-80 tons. The core patent of main API orlistat was awarded the 18th China Patent Award for Excellence. The quality and capability ofOrlistat, reaches the international advanced level and Orlistat is popular in Brazil, Germany, Korea, India, etc. The existing preparation production line meets the manufacturing requirements of capsule, granule, tablet and suppository etc. The new line under construction expands the scale of production. At present the core products are orlistat capsules, Donepezil Hydrochloride tablets, Ropigniro Hydrochloride tablets, Suplatast Tosilate granules and so on. The company is planning to build production base for traditional Chinese medicine granules and classic famous prescription. The total investment for this project is RMB900 million.
Zein owns a rich product catalog and plenty of follow-up products. Currently, the fist products are Orlistat, Donepezil Hydrochloride, Ropinirole hydrochloride and suplatast tosilate. The key products, including Talipexole Hydrochloride and Landiolol Hydrochloride will be marketed soon.
Zein’s domestic sales network covers 30 cities, including 2,000 hospitals and 40,000 drugstores. Zein’s APIs are exported to more than 20 countries worldwide including Korea, Brazil, India, Egypt.